Autonomy of Medical Professionals

The RCP has taken away the right for medical practitioners to exercise their professional clinical judgement.²³⁶

According to the ‘Medicines and Healthcare Regulatory Agency (MHRA) Review of Unlicensed Medicines’, they make the point that: “ Clinicians should have the ability in appropriate circumstances to exercise their professional judgement to commission the supply of an unlicensed medicine to meet the special needs of an individual patient ”.²³⁷

Taking away a doctor’s autonomy makes the RCP policy statement mandatory. The law is not fond of unresolved issues and will follow the generally accepted interpretation. The present case is the boycotting of all alternatives to levothyroxine sodium. The doctor who dares defy the medical guidelines for the benefit of the patient can find him/herself in substantial and costly disciplinary difficulties with the GMC, even if the doctor is treating his patient ethically and scientifically.

So doctors are fearful of the RCP’s influence upon the GMC. They fear losing their career and livelihood should they dare to diagnose or treat outside of this policy statement, which goes beyond the bounds of primary hypothyroidism. Fear of prosecution enforces compliance. Compliance stops them diagnosing and treating their patients properly. The RCP policy statement, because it goes beyond the bounds of primary hypothyroidism, is harming patients and doctors.

References

1. Joint Committee on Higher Medical Training, “Higher Medical Training Curriculum for Endocrinology and Diabetes Mellitus,” 2003, 5 Saint Andrews Place, Regent’s Park, London NW1 4LB

2. Good Medical Practice: Teaching and training, appraising and assessing. http://www.gmc-uk.org/guidance/good_medical_practice/teaching_training.asp

3. Map of Medicine: Royal College of Physicians Joint specialty societies. http://eng.mapofmedicine.com/evidence/map/thyroid_disorders1.html

4. Goldberg M, The Case For Euthyroid Hypometabolism, Am J Med Sc October, 1960 pgs 479-493

5. Goldberg M, Diagnosis of Euthyroid Hypometabolism, Am J Obst & Gynec, 81(5): 1053-1058, 1961

6. Baisier, WV, Hertoghe, J., Beekhaut, W., Thyroid Insufficiency? Is Thyroxine the Only Valuable Drug?, Journal of Nutritional and Environmental Medicine, Vol. 11, No. 3, September 2001, pages 159-166

7. Braverman LE, Ingbar SH, Keinwem S, Conversion of Thyroxine (T4) to Triiodothyronine (T3) in Athyreotic Human Subjects, The J Clin Invest, 1970

8. Danzi S, Ojamaa K, and Klein I, Triiodothyronine-Mediated Myosin Heavy Chain Gene Transcription in the Heart, Am J Phys Heart Circ Physiol, Feb 27, 2003

9. Eisenstein Z, Hagg S, Braverman LE, et al., Effect of Starvation on the Production and Peripheral Metabolism of 3,3',5' Triiodothyronine in Euthyroid Obese Subjects, J Clin Endocrinol Metab, 1978, 47(4): 889-893

10. Nomura S., et al. Reduced Peripheral Conversion of Thyroxine to Triiodothyronine in Patients with Hepatic Cirrhosis, J of Clin Invest, Sept 1975, 56(3): 643-652

11. Refetoff S, Dewind LT, DeGroot LJ, Familial Syndrome Combining Deaf-mutism, Stippled Epiphyses, Goiter and Abnormally High PBI: Possible Target Organ Refactoriness to Thyroid Hormone, J Clin Endocrinol Metab, 27:279, 1967

12. Refetoff S, Weiss RE, Usala SJ, The Syndromes of Resistance to Thyroid Hormone, Endocr Rev, 1993, 14(3):348-399

13. Weiss RE, Refetoff S, Treatment of Resistance to Thyroid Hormone – Primum Non Nocere, J Clin Endocr Metabol, 84(2):401-404.

14. Thyroid Patient Advocacy sponsored a registry of counterexamples, numbering just under 2000 (Mar. 2012). http://www.tpa-uk.org.uk/register_of_counterexamples.php

15. http://www.rcplondon.ac.uk/sites/default/files/the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdf

16. Saravanan P, Chau F, Roberts N, Vedhara K, Greenwood R, Dayan CM, 2002, Psychological Well-Being in Patients on "Adequate" Doses of L-Thyroxine Results of a Large, Controlled Community-Based Questionnaire Study, Clinical Endocrinology, 2002, 57: 577-585

17. Robert H. Seller, MD and Andrew B. Symons, MD, MS ‘Differential Diagnosis of Common Complaints’, 6th Edition. ISBN: 9781455707720

18. Differential Diagnosis (DDX) Definition: “The distinguishing of a disease or condition from others presenting with similar signs and symptoms,” Merriam-Webster

19. Differential Diagnosis (DDX) ”is a systematic method used to identify unknowns. This method, essentially a process of elimination, is used by taxonomists to identify living organisms, and by physicians and other qualified professionals to diagnose the specific disease in a patient. Not all medical diagnoses are differential ones: some diagnoses merely name a set of signs and symptoms that may have more than one possible cause, and some diagnoses are based on intuition or estimations of likelihood.” Wikipedia: http://en.wikipedia.org/wiki/Differential_diagnosis

20. Differential Diagnosis is a medical adaption of the process of elimination. These processes are based upon the logic of disjunctive syllogism, which is known from antiquity as modus tollendo poner

21. Geisler NL, Brooks RM, Come, Let Us Reason, Baker Book House, original printing 1990

22. A. P. Weetman. Whose Thyroid Hormone Replacement is it Anyway? Clin Endocrinol. 2006;64(3):231-233.

23. Sharpe M, Carson A, “Unexplained Somatic Symptoms, Functional Syndromes, and Somatization: Do We Need a Paradigm Shift?, Ann Intern Med, 2001, 134:926-930

24. Refetoff S, Weiss RE, Usala SJ, The Syndromes of Resistance to Thyroid Hormone, Endocr Rev, 1993, 14(3):348-399

25. Braverman LE, Ingbar SH, Keinwem S, Conversion of Thyroxine (T4) to Triiodothyronine (T3) in Athyreotic Human Subjects, The J Clin Invest, 1970, 49

26. Wrutniak-Cabello C, Casas F, Cabello G, Thyroid Hormone Action in Mitochondria, J Molec Endocrin, (26) 67-77, 2001

27. Vanderpump MPJ, Ahlquist JAO, Franklyn JA, et al., Consensus Statement for Good Practice and Audit Measures in the Management of Hypothyroidism and Hyperthyroidism, BMJ, August 1996

28. UK Guidelines for the Use of Thyroid Function Tests, The Association for Clinical Biochemistry, British Thyroid Association, British Thyroid Fndtn, 2006, www.british-thyroid-association.org/guidelines.htm

29. The Diagnosis and Management of Primary Hypothyroidism, Royal College of Physicians, 2008

30. Goldberg M, The Case For Euthyroid Hypometabolism, Am J Med Sc October, 1960 pgs 479-493

31. Baisier, WV, Hertoghe, J., Beekhaut, W., Thyroid Insufficiency? Is Thyroxine the Only Valuable Drug?, Journal of Nutritional and Environmental Medicine, Vol 11, No. 3, September 2001, pages 159-166

32. Turner S. Patient Counterexample Registry, Thyroid Patient Advocacy

33. Dillman E, Gale C, Green W, et al. Hypothermia in iron deficiency due to altered triiodithyroidine metabolism. Regulatory, Integrative and Comparative Physiology 1980;239(5):377-R381.

34. Smith SM, Johnson PE, Lukaski HC. In vitro hepatic thyroid hormone deiodination in iron-deficient rats: effect of dietary fat. Life Sci 1993;53(8):603-9.

35. Zimmermann MB, Kцhrle J. The Impact of Iron and Selenium Deficiencies on Iodine and Thyroid Metabolism: Biochemistry and Relevance to Public Health. Thyroid 2002;12(10): 867-78.

36. Beard J, tobin B, Green W. Evidence for Thyroid Hormone Deficiency in Iron-Deficient Anemic Rats. J. Nutr. 1989;119:772-778.

37. Jabbar A, Yawar A, Waseem S, Islam N, Ul Haque N, Zuberi L, Khan A, Akhter J. Vitamin B12 deficiency common in primary hypothyroidism. Department of Medicine, Aga Khan University, Karachi, Pakistan. 2008 May;58(5):258-61.

38. Julia Bбrsony, P. Lakatos, J. Fцldes and T. Fehйr. Effect of vitamin D3 loading and thyroid hormone replacement therapy on the decreased serum 25-hydroxyvitamin D level in patients with hypothyroidism: Acta Endocrinol November 1, 1986 113 329-334

39. B. CATARGI, F. PARROT-ROULAUD, C. COCHET, D. DUCASSOU, P. ROGER, and A. TABARIN. Thyroid. December 1999, 9(12): 1163-1166. doi:10.1089/thy.1999.9.1163. Published in Volume: 9 Issue 12: January 30, 2009

40. Bjшrn G. Nedrebш, Ottar Nygеrd, Per M. Ueland, and Ernst A. Lien; Plasma Total Homocysteine in Hyper- and Hypothyroid Patients before and during 12 Months of Treatment. Clinical Chemistry September 2001 vol. 47 no. 9 1738-1741

41. JOHN E. JONESt PAUL C. DESPER, STANLEY R. SHANE, AND EDMUND B. FLINK.Magnesium Metabolism in Hyperthyroidism and Hypothyroidism: Journal of Clinical Investigation. Vol. 45, No. 6, 1966

42. Lawrence Wilson, MD.COPPER TOXICITY SYNDROME Revised, July 2011, The Center For Development. http://www.drlwilson.com/articles/copper_toxicity_syndrome.htm

43. Vivek R Joshi, Ayaz K Mallick, Manjunatha Goud B K, Ravindra Maradi, Maheshwar G Reddy, Raghavendra Tey, Gaurav Shorey. Effect of serum copper concentration and ceruloplasmin on lipid parameters leading to increased propensity to cardiovascular risk. Department of Biochemistry, Melaka Manipal Medical College, Manipal University. ISSN: 0975-8585

44. Iham Amir Al-Juboori, Rafi Al-Rawi, Hussein Kadhem A-Hakeim. Estimation of Serum Copper, Manganese, Selenium, and

45. Zinc in Hypothyroidism Patients. IUFS Journal of Biology Short Communication 121 IUFS J Biol 2009, 68(2): 121-126

46. Rajagopal KR, Abbrecht PH, Derderian SS, Pickett C, Hofeldt F, Tellis CJ, Zwillich CW. Obstructive sleep apnea syndrome and hypothyroidism (a report of three cases)].Ann Intern Med. 1984 Oct; 101(4):491-4.

47. Rack SK, Makela EH. Hypothyroidism and depression: a therapeutic challenge Department of Behavioural Medicine and Psychiatry. Ann Pharmacother 2000 Oct; 34(10):1142-5

48. Jonathan Stephen Murray, Rubaraj Jayarajasingh, Petros Perros. Deterioration of symptoms after start of thyroid hormone replacementBMJ.2001 August 11; 323(7308):332-333

49. Annane D, Sйbille V, Charpentier C, Bollaert PE, Franзois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Trochй G, Chaumet-Riffaud P, Bellissant E.Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002 Aug 21;288(7):862-71.

50. C. Orian Truss, M.D. Restoration of Immunologic Competence to Candida Albicans [http://orthomolecular.org/library/jom/1980/pdf/1980-v09n04-p287.pdf]

51. Diabetes Care January 2011 vol. 34 no. Supplement 1 S11-S61

52. McDermott JH, Coss A, Walsh CH. Celiac disease presenting as resistant hypothyroidism. Thyroid. 2005 Apr;15(4):386-8.

53. BRUCE H. COHEN, MD, DEBORAH R. GOLD, MD. What we know so far.Cleveland Clinic Journal of Medicine Volume 68.No 7; July 2001

54. Rees-Jones RW, Larsen PR. Triiodothyronine and thyroxine content of desiccated thyroid tablets. Metabolism. 1977 Nov;26(11):1213-8

55. Mangieri CN, Lund MH. Potency of United States Pharmacopeia desiccated thyroid tablets as determined by the antigoitrogenic assay in rats. J Clin Endocrinol Metab. 1970 Jan;30(1):102-4

56. Gaby AR. Sub-laboratory hypothyroidism and the empirical use of Armour thyroid. Altern Med Rev. 2004 Jun;9(2):157-79

57. Hertoghe T, Lo Cascio A., Hertoghe J. Considerable improvement of hypothyroid symptoms with two combined T3-T4 medication in patients still symptomatic with thyroxine treatment alone. Anti-Aging Medicine (Ed. German Society of Anti-Aging Medicine-Verlag 2003) 2004; 32-43

58. Hertoghe T. Many conditions related to age reduce the conversion of thyroxine to triiodothyronine - a rationale for prescribing preferentially a combined T3 + T4 preparation in hypothyroid adults. Anti-Aging Medical Therapeutics 2000; IV: 138-53 T3-T4 (and T3) treatments work better than T4

59. Saravanan P, Simmons DJ, Greenwood R, Peters TJ, Dayan CM. Partial substitution of thyroxine (T4) with tri-iodothyronine in patients on T4 replacement therapy: results of a large community-based randomized controlled trial. Clin Endocrinol Metab. 2005 Feb;90(2):805-12

60. Kloppenburg M, Dijkmans BA, Rasker JJ. Effect of therapy for thyroid dysfunction on musculoskeletal symptoms. Clin Rheumatol. 1993 Sep;12(3):341-5

61. Hertoghe T, Lo Cascio A., Hertoghe J. Considerable improvement of hypothyroid symptoms with two combined T3-T4 medication in patients still symptomatic with thyroxine treatment alone. Anti-Aging Medicine, Ed. German Society of Anti-Aging Medicine-Verlag 2003- 2004; 32-43

62. Pareira VG, Haron ES, Lima-Neto N, Medeiros-Neto GA. Management of myxedema coma: report on three successfully treated cases with nasogastric or intravenous administration of triiodothyronine. J Endocrinol Invest. 1982;5:331-4

63. Chernow B, Burman KD, Johnson DL, McGuire RA, O'Brian JT, Wartofsky L, Georges LP. T3 may be a better agent than T4 in the critically ill hypothyroid patient: evaluation of transport across the blood-brain barrier in a primate model. Crit Care Med. 1983 Feb;11(2):99-104

64. Arlot S, Debussche X, Lalau JD, Mesmacque A, Tolani M, Quichaud J, Fournier A. Myxoedema coma: response of thyroid hormones with oral and intravenous high-dose L-thyroxine treatment. Intensive Care Med. 1991;17(1):16-8 T3-T4 treatment: adding T3 to T4 results in greater improvement of clinical symptoms and signs in hypothyroid patients

65. Benevicius R, Kazanavicius G, Zalinkovicius R, Prange AJ. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med.1999; 340: 424-9.

When T3 and T4 are both supplemented to the food simultaneously with goitrogens, a much better prevention of goiter is obtained than when solely T4 is added, even if T4 is given at doses 7 times higher those of T3-T4 treatments

66. Devlin WF, Watanabe H. Thyroxin-triiodothyronine concentrations in thryoid powders. J Pharm Sci. 1966 Apr;55(4):390-3

Дата добавления: 2015-10-29